parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (2035 nCPM)	1.00
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 275	0.85
pathways Reactome	6 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 14673

TCF12 in oligodendrocytes, braak+0.39 (p 0.297) → +0.44 (p 0.234)receipt 14680
TCF12 in dopamine neurons, braak+0.32 (p 0.402) → +0.15 (p 0.699)receipt 14681

receipt 14681: TCF12 in dopamine neurons, braak

power: full sample +0.22 (p 0.384, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.25 (p 0.323, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.35 (p 0.159, n 18). could be the mix.
skeptic: leave-one-out range +0.11 to +0.38, sign flips 0; without severely affected donors +0.22 (p 0.384, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TCF12 in dopamine neurons.

case closed: nothing better to follow up.

receipt 14680: TCF12 in oligodendrocytes, braak

power: full sample +0.39 (p 0.111, n 18), 95% CI -0.10 to +0.72. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.37 (p 0.132, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.41 (p 0.087, n 18). could be the mix.
skeptic: leave-one-out range +0.31 to +0.49, sign flips 0; without severely affected donors +0.39 (p 0.111, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TCF12 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts